Clinical trial
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With…
NCT00064974 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00064974 |
|---|---|
| Title | Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes |
| Official title | A Multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 215 |
| Start date | Jun 1, 2003 |
| Primary completion | Jan 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Jul 17, 2003 |
| Last update posted | Apr 4, 2013 |
| Countries | Australia, Belgium, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Russia, Spain, Sweden and 3 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: